newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachm